Two of the challenges in thr early stages of a pharmaceutical are a limited supply of protein to use in formulation screening studies, and a need to obtain stability data quickly to initiate tox studies. In this poster, scientists at Catalent Biologics outline a method of utilizing a high-throughput, microwell plate platform to economically screen a monoclonal antibody (mAb) in 96 formulations.
Conducting a pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage. Read how Catalent Biologics utilizes automation, specifically the Uncle platform, during formulation development.
Catalent Biologics is your one integrated partner with the expertise to get your biologic to market faster. We have the passion to help you accelerate, simplify, and de-risk your next biologic from development and manufacturing, to fill/finish, clinical supply, and commercial launch.